2026 MIDD Webinar Series | The Reference Corrected Visual Predictive Checks & Question of Interest Oriented Model Evaluation

Includes a Live Web Event on 11/04/2026 at 12:00 PM (EST)

The ICH M15 Guideline “General Principles for MIDD” stresses the importance of performing model evaluation targeting the Question of Interest (QoI) that model is intended to help to answer. In this presentation we elaborate on how reference corrected visual predictive check (rcVPC) methodology can be used for this purpose. The rcVPC can provide an efficient and more easily communicable tool to validate models, increasing confidence in model-informed decision-making among broader, non-modeling stakeholders.

The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.

Moustafa Ibrahim

Global Clinical Pharmacology Lead

Astrazeneca

Moustafa M. A. Ibrahim obtained his Ph.D. in Pharmacometrics from Uppsala University, Sweden. Following his Ph.D., Moustafa joined Pharmetheus AB as MIDD Consultant, where he provided pharmacometrics expertise across the spectrum of drug development, from non-clinical studies through late-stage clinical development and regulatory submissions. In 2024, Moustafa joined the Clinical Pharmacology and Safety Sciences Department at AstraZeneca, within the Rare Disease Unit, as a Global Clinical Pharmacology Lead. In this role, he provides scientific and strategic leadership for multiple global development programs to inform dose selection, optimize study design, support regulatory interactions, and enable data-driven decision-making throughout clinical development.

Martin Bergstrand

Principal Consultant and MIDD Platform Science Lead

Pharmetheus

Martin obtained his PhD in Pharmacometrics from Uppsala University. He has 20+ years of drug development experience in areas such as metabolic disorders, autoimmune disease, infectious disease, hematological disorders etc. In 2012 Martin co-founded the consulting company Pharmetheus AB. In the consultant role he has been engaged as strategic advisor on behalf of multiple clients and acted as the main responsible consultant for 50+ pharmacometric data analysis projects on behalf of more than 20 different clients. The projects have ranged from pre-clinical translational projects to submission ready large-scale phase III PKPD analysis. These analyses have among other things contributed to 5+ successful NDA filings.

Key:

Complete

Failed

Available

Locked

MIDD Series | The Reference Corrected Visual Predictive Checks & Question of Interest Oriented Model Evaluation

11/04/2026 at 12:00 PM (EST) | 60 minutes

11/04/2026 at 12:00 PM (EST) | 60 minutes The ICH M15 Guideline “General Principles for MIDD” stresses the importance of performing model evaluation targeting the Question of Interest (QoI) that model is intended to help to answer. In this presentation we elaborate on how reference corrected visual predictive check (rcVPC) methodology can be used for this purpose. The rcVPC can provide an efficient and more easily communicable tool to validate models, increasing confidence in model-informed decision-making among broader, non-modeling stakeholders.

You must register to access.